celecoxib,ipilimumab,nivolumab
bms
['niche,(-niche 2),(-niche-2),(-niche2)']
dr chalabi shows almost 30% response rate to neoadjuvant io (nio) in pmmr crc with cd8+pd1+ t cells predicting response (small cohort) and highlights future nio trial design for niche #sitc22 